Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 192

1.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1602268. [Epub ahead of print]

PMID:
31014142
2.

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.

Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, Secreto CR, Call T, Shanafelt TD, Leis JF, Warner SL, Bearss DJ, Ghosh AK, Kay NE.

Oncotarget. 2018 Dec 14;9(98):37173-37184. doi: 10.18632/oncotarget.26444. eCollection 2018 Dec 14.

3.

Prospective, double-blind, randomized clinical trial comparing an ERAS pathway with ketorolac and pregabalin versus standard of care plus placebo during live donor nephrectomy for kidney transplant.

Campsen J, Call T, Allen CM, Presson AP, Martinez E, Rofaiel G, Kim RD.

Am J Transplant. 2018 Dec 27. doi: 10.1111/ajt.15242. [Epub ahead of print]

PMID:
30589514
4.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.

PMID:
30575108
5.

Addendum: Effects of a 5-HT1B Receptor Agonist on Locomotion and Reinstatement of Cocaine-Conditioned Place Preference after Abstinence from Repeated Injections in Mice.

Der-Ghazarian TS, Call T, Scott SN, Dai K, Brunwasser SJ, Noudali SN, Pentkowski NS, Neisewander JL.

Front Syst Neurosci. 2018 Nov 7;12:48. doi: 10.3389/fnsys.2018.00048. eCollection 2018. No abstract available.

6.

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA.

Br J Haematol. 2018 Nov;183(3):421-427. doi: 10.1111/bjh.15545. Epub 2018 Aug 16.

PMID:
30117139
7.

Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, Habermann TM, Cerhan JR, Stapleton JT.

Br J Haematol. 2018 Sep;182(5):644-653. doi: 10.1111/bjh.15416. Epub 2018 May 29.

PMID:
29808922
8.

PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.

He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL.

Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.

PMID:
29762141
9.

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, Weinberg JB, Benavente Y, Casabonne D, Liebow M, Nieters A, Hjalgrim H, Melbye M, Glimelius B, Adami HO, Boffetta P, Brennan P, Maynadie M, McKay J, Cocco PL, Shanafelt TD, Call TG, Norman AD, Hanson C, Robinson D, Chaffee KG, Brooks-Wilson AR, Monnereau A, Clavel J, Glenn M, Curtin K, Conde L, Bracci PM, Morton LM, Cozen W, Severson RK, Chanock SJ, Spinelli JJ, Johnston JB, Rothman N, Skibola CF, Leis JF, Kay NE, Smedby KE, Berndt SI, Cerhan JR, Caporaso N, Slager SL.

Blood. 2018 Jun 7;131(23):2541-2551. doi: 10.1182/blood-2017-11-814608. Epub 2018 Apr 19.

PMID:
29674426
10.

Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.

Kay NE, LaPlant BR, Pettinger AM, Call TG, Leis JF, Ding W, Parikh SA, Conte MJ, Bowen DA, Shanafelt TD.

Expert Rev Hematol. 2018 Apr;11(4):337-349. doi: 10.1080/17474086.2018.1442716. Epub 2018 Feb 26.

PMID:
29460654
11.

Platinum-free, graphene based anodes and air cathodes for single chamber microbial fuel cells.

Call TP, Carey T, Bombelli P, Lea-Smith DJ, Hooper P, Howe CJ, Torrisi F.

J Mater Chem A Mater. 2017 Dec 7;5(45):23872-23886. doi: 10.1039/c7ta06895f. Epub 2017 Nov 2.

12.

Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.

Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD.

Haematologica. 2018 Jun;103(6):e237-e240. doi: 10.3324/haematol.2017.183194. Epub 2018 Feb 1. No abstract available.

13.

Running exercise mitigates the negative consequences of chronic stress on dorsal hippocampal long-term potentiation in male mice.

Miller RM, Marriott D, Trotter J, Hammond T, Lyman D, Call T, Walker B, Christensen N, Haynie D, Badura Z, Homan M, Edwards JG.

Neurobiol Learn Mem. 2018 Mar;149:28-38. doi: 10.1016/j.nlm.2018.01.008. Epub 2018 Feb 9.

14.

Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease.

Goyal G, Shah MV, Call TG, Hook CC, Hogan WJ, Go RS.

Blood Cancer J. 2017 Dec 15;7(12):647. doi: 10.1038/s41408-017-0034-7. No abstract available.

15.

Efficacy of biological agents in the treatment of Erdheim-Chester disease.

Goyal G, Shah MV, Call TG, Litzow MR, Wolanskyj-Spinner AP, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Hook CC, Hogan WJ, Go RS.

Br J Haematol. 2018 Nov;183(3):520-524. doi: 10.1111/bjh.14997. Epub 2017 Oct 30. No abstract available.

PMID:
29082516
16.

Effects of a 5-HT1B Receptor Agonist on Locomotion and Reinstatement of Cocaine-Conditioned Place Preference after Abstinence from Repeated Injections in Mice.

Der-Ghazarian TS, Call T, Scott SN, Dai K, Brunwasser SJ, Noudali SN, Pentkowski NS, Neisewander JL.

Front Syst Neurosci. 2017 Oct 10;11:73. doi: 10.3389/fnsys.2017.00073. eCollection 2017. Erratum in: Front Syst Neurosci. 2018 Nov 07;12:48.

17.

Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.

Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Am J Hematol. 2017 Dec;92(12):1362-1369. doi: 10.1002/ajh.24915. Epub 2017 Oct 19.

18.

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ.

N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.

19.

Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.

Chang TW, Weaver AL, Shanafelt TD, Habermann TM, Wriston CC, Cerhan JR, Call TG, Brewer JD.

Int J Dermatol. 2017 Nov;56(11):1125-1129. doi: 10.1111/ijd.13653. Epub 2017 Jul 7.

20.

Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.

Goyal G, Shah MV, Hook CC, Wolanskyj AP, Call TG, Rech KL, Go RS.

Br J Haematol. 2018 Aug;182(4):579-581. doi: 10.1111/bjh.14818. Epub 2017 Jun 27. No abstract available.

PMID:
28653448

Supplemental Content

Loading ...
Support Center